Sign Out
Prevention of urinary tract toxicity of oxazaphosphorines (e.g. ifosfamide, cyclophosphamide or trofosfamide).
In the case of a tumour therapy with ifosfamide, MESNA Stada must always be given. In the case of a tumour therapy with cyclophosphamide or trofosfamide, MESNA Stada must always be given when dosages above 10 mg/kg are used and in patients at risk. Risks are in particular: previous radiation therapy in the area of the true pelvis, cystitis following previous therapy with ifosfamide, cyclophosphamide or trofosfamide and a history of uropathy.
